Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead program is CHM 1101, a novel CAR T therapy, for the treatment of patients with Glioblastoma.
Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference
